Access cutting-edge i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Little Rock location
Access i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. treatment provided free
Check if you qualify for this i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. clinical trial in Little Rock, AR
No-Cost Study Care
Local to Little Rock
Convenient for AR residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment with teclistamab, a B-cell maturation antigen (BCMA)-directed T-cell engager (anti-BCMAxCD3 bispecific antibody), will be offered monitored drug discontinuation. Teclistamab is typically dosed on a regular schedule (every 1-4 weeks) indefinitely until disease p
Sponsor: Abramson Cancer Center at Penn Medicine
Yes, this clinical trial (NCT05932680) has an active research site in Little Rock, AR that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. treatment options in Little Rock, AR, this clinical trial (NCT05932680) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all i cannot determine a primary medical condition from this data. the study title mentions "teclistamab" (a drug) and the listed condition is "other:off drug surveillance" which refers to monitoring rather than a medical condition. there are no keywords or meaningful brief summary provided to identify what health issue this study addresses. clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Little Rock — not just this study.
Browse Multiple Myeloma Trials in Little Rock →